JP2018538304A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538304A5
JP2018538304A5 JP2018531333A JP2018531333A JP2018538304A5 JP 2018538304 A5 JP2018538304 A5 JP 2018538304A5 JP 2018531333 A JP2018531333 A JP 2018531333A JP 2018531333 A JP2018531333 A JP 2018531333A JP 2018538304 A5 JP2018538304 A5 JP 2018538304A5
Authority
JP
Japan
Prior art keywords
substituted
independently
alkyl
cycloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018531333A
Other languages
English (en)
Japanese (ja)
Other versions
JP6948322B2 (ja
JP2018538304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/066750 external-priority patent/WO2017106396A1/en
Publication of JP2018538304A publication Critical patent/JP2018538304A/ja
Publication of JP2018538304A5 publication Critical patent/JP2018538304A5/ja
Application granted granted Critical
Publication of JP6948322B2 publication Critical patent/JP6948322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018531333A 2015-12-16 2016-12-15 Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン Active JP6948322B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267997P 2015-12-16 2015-12-16
US62/267,997 2015-12-16
PCT/US2016/066750 WO2017106396A1 (en) 2015-12-16 2016-12-15 Heteroarylhydroxypyrimidinones as agonists of the apj receptor

Publications (3)

Publication Number Publication Date
JP2018538304A JP2018538304A (ja) 2018-12-27
JP2018538304A5 true JP2018538304A5 (enExample) 2020-01-30
JP6948322B2 JP6948322B2 (ja) 2021-10-13

Family

ID=57708840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531333A Active JP6948322B2 (ja) 2015-12-16 2016-12-15 Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン

Country Status (21)

Country Link
US (1) US10669261B2 (enExample)
EP (1) EP3390400B1 (enExample)
JP (1) JP6948322B2 (enExample)
KR (1) KR102742744B1 (enExample)
CN (1) CN108602813B (enExample)
AR (1) AR107061A1 (enExample)
AU (1) AU2016372048B2 (enExample)
BR (1) BR112018012112A2 (enExample)
CA (1) CA3008630A1 (enExample)
CL (1) CL2018001621A1 (enExample)
CO (1) CO2018007221A2 (enExample)
EA (1) EA036736B1 (enExample)
ES (1) ES2854733T3 (enExample)
HK (1) HK1255163A1 (enExample)
IL (1) IL259947B (enExample)
MX (1) MX380669B (enExample)
PE (1) PE20181487A1 (enExample)
SG (1) SG11201804674UA (enExample)
TW (1) TW201725203A (enExample)
UY (1) UY37026A (enExample)
WO (1) WO2017106396A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189453A (en) 2015-06-03 2022-02-14 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
CA3001974A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
WO2017096130A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
PT3390395T (pt) 2015-12-16 2020-11-03 Loxo Oncology Inc Compostos úteis como inibidores de quinase
MA43761A (fr) 2016-03-24 2021-05-05 Bristol Myers Squibb Co 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
KR102521955B1 (ko) 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
US10508104B2 (en) 2016-06-14 2019-12-17 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
EP3526198B1 (en) 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH08311041A (ja) 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 複素環化合物およびその剤
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
NZ520752A (en) * 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
AU2001280590A1 (en) 2000-07-18 2002-01-30 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
WO2004094408A1 (en) 2003-04-23 2004-11-04 Pharmacia & Upjohn Company Llc Substituted pyrimidinones and pyrimidinthiones as crf antagonists
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005041888A2 (en) 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
JP2007518711A (ja) 2003-12-19 2007-07-12 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP4517349B2 (ja) 2004-07-28 2010-08-04 宇部興産株式会社 ピリミジン−4−オン化合物の製造方法
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 c-Met의 억제제 및 이의 용도
EP2016056A4 (en) 2006-04-21 2010-11-10 Univ Boston IONIC VISCOELASTIC AND VISCOELASTIC SALTS
EP2079707B1 (de) 2006-10-10 2014-12-03 proionic GmbH & Co KG Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2279192B1 (en) 2008-05-28 2013-10-30 Merck Patent GmbH Ionic liquids
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
WO2010072696A2 (de) 2008-12-22 2010-07-01 Basf Se Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern
US9040538B2 (en) 2009-05-21 2015-05-26 Universite Laval Pyrimidines as novel therapeutic agents
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
KR20140039242A (ko) 2011-05-31 2014-04-01 메르크 파텐트 게엠베하 전해질 제형
TWI567084B (zh) 2011-05-31 2017-01-21 麥克專利有限公司 含有氫-三氰-硼酸根陰離子之化合物
CN102903954B (zh) 2011-07-25 2015-06-03 微宏动力系统(湖州)有限公司 含有离子液体电解质的锂离子二次电池
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
CN110664816A (zh) 2012-06-07 2020-01-10 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
HUE031733T2 (en) * 2012-09-21 2017-07-28 Sanofi Sa Benzimidazole carboxylic acid amide derivatives for the treatment of metabolic or cardiovascular diseases
WO2014056844A1 (en) 2012-10-10 2014-04-17 Basf Se Ionic liquids based on oxalic acid mono esters
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
HK1212235A1 (en) 2012-11-16 2016-06-10 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
ES2906062T3 (es) 2013-11-29 2022-04-13 Proionic Gmbh Procedimiento para la unión de un material termoplástico por medio de radiación de microondas
KR101550846B1 (ko) 2014-01-29 2015-09-07 한국과학기술연구원 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도
KR101531023B1 (ko) 2014-05-27 2015-06-23 한국과학기술연구원 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유
US10570128B2 (en) * 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
EP3152200A1 (en) * 2014-06-06 2017-04-12 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
MY189453A (en) * 2015-06-03 2022-02-14 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
CA3001974A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
WO2017096130A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
MA43761A (fr) 2016-03-24 2021-05-05 Bristol Myers Squibb Co 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj
KR102521955B1 (ko) 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
US10508104B2 (en) 2016-06-14 2019-12-17 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
EP3526198B1 (en) 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists

Similar Documents

Publication Publication Date Title
JP2018538304A5 (enExample)
IL259947A (en) The troirylhydroxypyrimidinones as apj receptor agonists
JP2019517475A5 (enExample)
JP2018501285A5 (enExample)
JP2019532072A5 (enExample)
JP2019518041A5 (enExample)
JP2019520398A5 (enExample)
JP2020500869A5 (enExample)
JP2019031560A5 (enExample)
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
JP2019519476A5 (enExample)
JP2021507900A5 (enExample)
JP2018536648A5 (enExample)
JP2018535999A5 (enExample)
JP2016121196A5 (enExample)
JP2014521688A5 (enExample)
JP2019509978A5 (enExample)
KR910009692A (ko) 인돌 유도체
IL298983A (en) Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors
JP2014513704A5 (enExample)
RU2018104092A (ru) Бициклические лактамы и способы их применения
JP2019518036A5 (enExample)
JP2017504640A5 (enExample)
US9988390B2 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
NZ601698A (en) Fatty acid fumarate derivatives and their uses